Vertex Pharmaceuticals Incorporated’s VRTX shares were down in pre-market trading on news that the company will be stopping one of the phase III studies being conducted on a VX-661 - ivacaftor (trade ...
Vertex said that the results indicate that a triple combination regimen may provide more benefit to this particular patient population and expects to initiate a study of a next-generation corrector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results